Insud Pharma
Mauricio Gil Barahona currently serves as Group Internal Audit Manager at Insud Pharma since March 2017, where responsibilities include defining and developing the Internal Audit Function and collaborating on the Internal Audit Plan. Prior experience includes positions as Group Internal Auditor at Insud Pharma, Senior Internal Auditor at Dufry Group, and Internal Auditor at World Duty Free Group, focusing on operational audits and compliance. Mauricio's career began at Ernst & Young as a Senior Internal Auditor in Advisory Risk Services, with expertise spanning sectors such as Oil & Gas, Pharma, and Retail. Educational qualifications include an Executive MBA from ESIC Business & Marketing School, a Business/Data Visualization course from IE Business School, and multiple certifications from the Institute of Internal Auditors, including COSO ERM and COSO Internal Control.
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.